中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明

doi:10.3969/j.issn.1673-5765.2024.04.007

摘要/Abstract

摘要： 中国缺血性卒中（ischemic stroke，IS）及TIA疾病负担沉重。LDL-C水平升高是卒中复发的独立危险因素，积极评估患者LDL-C不达标的原因，制订进一步治疗策略、监测频率以提高达标率具有重要临床意义。为加强医务工作者对IS及TIA疾病长期管理及监测的认识，规范长期血脂管理临床实践，中国卒中学会医疗质量管理与促进分会组织相关脑血管病临床医学专家，基于循证证据和临床实践、经多轮专家意见收集和研讨，拟定本科学声明。本科学声明对IS及TIA患者长期血脂管理、长期血脂监测及重点患者血脂管理等方面进行了阐述，以期为提升IS及TIA患者的长期血脂管理临床规范提供参考。

关键词: 缺血性卒中; 短暂性脑缺血发作; 低密度脂蛋白胆固醇; 血脂管理; 科学声明

Abstract: The disease burden is substantial among Chinese patients with ischemic stroke (IS) and TIA. High LDL-C level is an independent risk factor for stroke recurrence. It is of clinical significance to assess the reasons resulting in unfavorable LDL-C control in patients, develop further treatment strategies, monitor frequencies to improve the LDL-C target attainment rate. To strengthen the understanding of medical workers on the long-term management and monitoring of IS and TIA, and standardize clinical practice of long-term lipid management, this scientific statement was formulated by clinical experts in cerebrovascular disease organized by the Chinese Stroke Association’s Subcommittee on Medical Quality Management and Promotion. The scientific statement, based on evidence-based research, clinical practice, multiple rounds of expert opinion collection, and thorough discussions, elaborated on long-term lipid management, monitoring, and lipid management in high-risk patients in IS and TIA. It aims to provide reference for improving clinical in long-term lipid management for IS and TIA patients.

Key words: Ischemic stroke; Transient ischemic attack; Low density lipoprotein cholesterol; Lipid management; Scientific statement

中图分类号:

中国卒中学会医疗质量管理与促进分会, 《中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明》编写组. 中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明[J]. 中国卒中杂志, 2024, 19(4): 440-451.

Chinese Stroke Association’s Subcommittee on Medical Quality Management and Promotion, Writing Group of Scientific Statement on the Long-Term Lipid Management in Patients with Ischemic Stroke and Transient Ischemic Attack in China. Scientific Statement on the Long-Term Lipid Management in Patients with Ischemic Stroke and Transient Ischemic Attack in China[J]. Chinese Journal of Stroke, 2024, 19(4): 440-451.

参考文献

[1] XU J，ZHANG X，JIN A M，et al. Trends and risk factors associated with stroke recurrence in China，2007018[J/OL]. JAMA Netw Open，2022，5（6）：e2216341[2024-01-11]. https://doi.org/10.1001/jamanetworkopen.2022.16341.
[2] GU H Q，YANG K X，YANG X，et al. Guideline-directed low-density lipoprotein management in high-risk ischemic stroke or transient ischemic attack admissions in China from 2015 to 2019[J/OL]. Ann Transl Med，2021，9（15）：1224[2024-01-11].
https://doi.org/10.21037/atm-21-1467.
[3] WANG C J，WANG Y L，LI Z X，et al. The management of LDL cholesterol and predictors of goal achievement in stroke patients in China：a cross-sectional study[J]. CNS Neurosci Ther，2016，22（7）：577-583.
[4] AMARENCO P，LAVALLÉE P C，MONTEIRO TAVARES L，et al. Five-year risk of stroke after TIA or minor ischemic stroke[J]. N Engl J Med，2018，378（23）：2182-2190.
[5] FULCHER J，O’CONNELL R，VOYSEY M，et al. Efficacy and safety of LDL-lowering therapy among men and women：meta-analysis of individual data from 174 000 participants in 27 randomised trials[J]. Lancet，2015，385（9976）：1397-1405.
[6] BAIGENT C，BLACKWELL L，EMBERSON J，et al. Efficacy and safety of more intensive lowering of LDL cholesterol：a meta-analysis of data from 170 000 participants in 26 randomised trials[J]. Lancet，2010，376（9753）：1670-1681.
[7] RIDKER P M，DANIELSON E，FONSECA F A，et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med，2008，359（21）：2195-2207.
[8] AMARENCO P，GOLDSTEIN L B，SZAREK M，et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack：the stroke prevention by aggressive reduction in cholesterol levels（SPARCL）trial[J]. Stroke，2007，38（12）：3198-3204.
[9] AMARENCO P，KIM J S，LABREUCHE J，et al. A comparison of two LDL cholesterol targets after ischemic stroke[J/OL]. N Engl J Med，2020，382（1）：9[2024-01-11]. https://doi.org/10.1056/NEJMoa1910355.
[10] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国缺血性卒中和短暂性脑缺血发作二级预防指南2022[J]. 中华神经科杂志，2022，55（10）：1071-1110.
Chinese Society of Neurology，Chinese Stroke Society. Chinese guideline for the secondary prevention of ischemic stroke and transient ischemic attack 2022[J]. Chin J Neurol，2022，55（10）：1071-1110.
[11] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（2023年）[J]. 中国循环杂志，2023，38（3）：237-271.
Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guidelines for lipid management（2023）[J]. Chinese Circulation Journal，2023，38（3）：237-271.
[12] SABATINE M S，GIUGLIANO R P，KEECH A C，et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med，2017，376（18）：1713-1722.
[13] SCHWARTZ G G，STEG P G，SZAREK M，et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med，2018，379（22）：2097-2107.
[14] RAAL F J，KALLEND D，RAY K K，et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia[J]. N Engl J Med，2020，382（16）：1520-1530.
[15] CANNON C P，BLAZING M A，GIUGLIANO R P，et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med，2015，372（25）：2387-2397.
[16] TOTH P P，WORTHY G，GANDRA S R，et al. Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia[J/OL]. J Am Heart Assoc，2017，6（10）：e005367[2024-01-11]. https://doi.org/10.1161/JAHA.116.005367.
[17] RAY K K，WRIGHT R S，KALLEND D，et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med，2020，382（16）：1507-1519.
[18] RAY K K，RAAL F J，KALLEND D G，et al. Inclisiran and cardiovascular events：a patient-level analysis of phase Ⅲ trials[J]. Eur Heart J，2023，44（2）：129-138.
[19] HUO Y，LESOGOR A，LEE C W，et al. Efficacy and safety of inclisiran in Asian patients：results from ORION-18[J]. JACC Asia，2024，4（2）：123-134.
[20] RAY K K，TROQUAY R P T，VISSEREN F L J，et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol（ORION-3）：results from the 4-year open-label extension of the ORION-1 trial[J]. Lancet Diabetes Endocrinol，2023，11（2）：109-119.
[21] LI J J，LIU H H，WU N Q，et al. Statin intolerance：an updated，narrative review mainly focusing on muscle adverse effects[J]. Expert Opin Drug Metab Toxicol，2020，16（9）：837-851.
[22] MCKENNEY J M，DAVIDSON M H，JACOBSON T A，et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force[J/OL]. Am J Cardiol，2006，97（8a）：89c-94c[2024-01-11]. https://doi.org/10.1016/j.amjcard.2006.02.030.
[23] STROES E S，THOMPSON P D，CORSINI A，et al. Statin-associated muscle symptoms：impact on statin therapy—European Atherosclerosis Society Consensus Panel statement on assessment，aetiology and management[J]. Eur Heart J，2015，36（17）：1012-1022.
[24] MAKI K C，RIDKER P M，BROWN W V，et al. An assessment by the Statin Diabetes Safety Task Force：2014 update[J/OL]. J Clin Lipidol，2014，8（3 Suppl）：S17-29[2024-01-11]. https://doi.org/10.1016/j.jacl.2014.02.012.
[25] MAY H T，KNOWLTON K U，ANDERSON J L，et al. High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease：results from the IMPRES study[J]. Eur Heart J Qual Care Clin Outcomes，2022，8（3）：352-360.
[26] SLEJKO J F，HO M，ANDERSON H D，et al. Adherence to statins in primary prevention：yearly adherence changes and outcomes[J]. J Manag Care Pharm，2014，20（1）：51-57.
[27] ZHAO Y M，ZABRISKI S，BERTRAM C. Associations between statin adherence level，health care costs，and utilization[J]. J Manag Care Spec Pharm，2014，20（7）：703-713.
[28] O’DONOGHUE M L，GIUGLIANO R P，WIVIOTT S D，et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease[J]. Circulation，2022，146（15）：1109-1119.
[29] KOREN M J，SABATINE M S，GIUGLIANO R P，et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia[J]. J Am Coll Cardiol，2019，74（17）：2132-2146.
[30] GIUGLIANO R P，MACH F，ZAVITZ K，et al. Cognitive function in a randomized trial of evolocumab[J]. N Engl J Med，2017，377（7）：633-643.
[31] FOX K M，TAI M H，KOSTEV K，et al. Treatment patterns and low-density lipoprotein cholesterol（LDL-C）goal attainment among patients receiving high- or moderate-intensity statins[J]. Clin Res Cardiol，2018，107（5）：380-388.
[32] ZHANG M，DENG Q，WANG L H，et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults：a nationally representative survey of 163 641 adults[J/OL]. Int J Cardiol，2018，260：196-203[2024-01-11]. https://doi.org/10.1016/j.ijcard.2017.12.069.
[33] WANG Y J，ZHAO X Q，LIU L P，et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China：the Chinese intracranial atherosclerosis（CICAS）study[J]. Stroke，2014，45（3）：663-669.
[34] RESTREPO L，BANG O Y，OVBIAGELE B，et al. Impact of hyperlipidemia and statins on ischemic stroke outcomes after intra-arterial fibrinolysis and percutaneous mechanical embolectomy[J]. Cerebrovasc Dis，2009，28（4）：384-390.
[35] CHIMOWITZ M I，KOKKINOS J，STRONG J，et al. The warfarin-aspirin symptomatic intracranial disease study[J]. Neurology，1995，45（8）：1488-1493.
[36] TURAN T N，NIZAM A，LYNN M J，et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial[J]. Neurology，2017，88（4）：379-385.
[37] MOTTILLO S，FILION K B，GENEST J，et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis[J]. J Am Coll Cardiol，2010，56（14）：1113-1132.
[38] CHEHADE J M，GLADYSZ M，MOORADIAN A D. Dyslipidemia in type 2 diabetes：prevalence，pathophysiology，and management[J]. Drugs，2013，73（4）：327-339.
[39] TURNER R C，MILLNS H，NEIL H A，et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus：United Kingdom prospective diabetes study（UKPDS：23）[J]. BMJ，1998，316（7134）：823-828.
[40] PYŎRÄLÄ K，PEDERSEN T R，KJEKSHUS J，et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease：a subgroup analysis of the Scandinavian simvastatin survival study（4S）[J]. Diabetes Care，1997，20（4）：614-620.
[41] COLHOUN H M，BETTERIDGE D J，DURRINGTON P N，et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study（CARDS）：multicentre randomised placebo-controlled trial[J]. Lancet，2004，364（9435）：685-696.
[42] ZHENG H，JIANG S，LIN L. [Advances in diagnosis and treatment of familial hypercholesterolemia][J]. Nan Fang Yi Ke Da Xue Xue Bao，2023，43（1）：153-156.
[43] BENN M，WATTS G F，TYBJAERG-HANSEN A，et al. Familial hypercholesterolemia in the Danish general population：prevalence，coronary artery disease，and cholesterol-lowering medication[J]. J Clin Endocrinol Metab，2012，97（11）：3956-3964.
[44] SHI Z M，YUAN B J，ZHAO D，et al. Familial hypercholesterolemia in China：prevalence and evidence of underdetection and undertreatment in a community population[J]. Int J Cardiol，2014，174（3）：834-836.
[45] MACH F，BAIGENT C，CATAPANO A L，et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias：lipid modification to reduce cardiovascular risk[J]. Eur Heart J，2020，41（1）：111-188.
[46] DYRBUŚ K，GĄSIOR M，PENSON P E，et al. Extreme cardiovascular risk—do we need a new risk category?[J]. Eur Heart J，2022，43（19）：1784-1786.